Tell us what you think about the new Article Page. Send us feedback
Accera, Inc. Announces Culmination of Lost & Found Campaign: Company Donates $25,000 to the Alzheimer's Foundation of America for National Memory Screening Day
BROOMFIELD, Colo., Nov. 17 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced today the culmination of its "Lost & Found" campaign, an online educational initiative whereby each visit to www.lostandfoundcampaign.com prompted a donation by Accera to support the Alzheimer's Foundation of America (AFA).
(Photo: http://www.newscom.com/cgi-bin/prnh/20091117/NY12879 )
All funds generated through this initiative, which totaled $25,000, are being donated to AFA today for "National Memory Screening Day" to further the organization's efforts to support individuals with Alzheimer's disease and their families. Eric J. Hall, president and CEO of AFA, said, "We remain grateful of organizations and companies such as Accera that have repeatedly demonstrated their commitment to individuals facing this devastating disease and to the cause in general."
National Memory Screening Day, an annual initiative sponsored by AFA, provides free, confidential memory screenings to individuals concerned about memory loss with the objective of early detection and intervention. Qualified healthcare professionals offer the face-to-face screenings and distribute educational materials about memory concerns and successful aging in communities across the nation.
Steve Orndorff, Ph.D., President and CEO of Accera, Inc., stated, "We are very pleased with the success of this campaign and are eager to continue our efforts in the fight against Alzheimer's disease." He continued, "With this donation, we hope to further improve the quality of life for patients and caregivers."
About Axona(TM)
Axona is a first-in-class prescription medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing ketone bodies as an alternative energy source for brain cells that have defective energy metabolism and can no longer utilize glucose. Axona has been shown to safely improve cognitive function and memory in AD patients and in pre-clinical animal models of dementia. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies. Axona is a medical food as defined by the Orphan Drug Act and is regulated by the Food and Drug Administration. For more information about Axona, please visit www.about-axona.com or ask your physician.
About Accera, Inc.
Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets Axona in the US. Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Accera is engaged in the research, development and commercialization of other clinical applications for Axona in acute and chronic neurodegenerative diseases. For more information about Accera, please visit www.accerapharma.com.
Contacts:
Accera, Inc.
Steve Orndorff, Ph.D.
President and CEO
sorndorff@accerapharma.com
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach
amielach@tiberendstrategicadvisors.com
or
Farrell Denby
fdenby@tiberendstrategicadvisors.com
Add Alert